Shenzhen Bioeasy Biotechnology Co 300942.SZ · CNY

Its shares trade on Shenzhen under the ticker 300942.SZ. It has been listed since 9 February 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥263.2m and net income of CN¥13.7m. At that date it held total assets of CN¥1.52bn and shareholders' equity of CN¥904.1m.

Shenzhen Bioeasy Biotechnology Co., Ltd. engages in the research and development, production, and sale of food and drug safety and clinical diagnostic products. The company is headquartered in Shenzhen, Guangdong. The company went IPO on 2021-02-09. The Company’s main products are food safety rapid testing reagents, rapid testing instruments, related testing services and in vitro diagnostic point-of-car testing (POCT) products, such as colloidal gold immunochromatographic test papers, enzyme-linked immunoassay (ELISA) kits, nucleic acids extraction kit, portable food rapid analysis system, infectious disease detection series and fluorescence immunoassay analyzer, etc. Its products are mainly used in dairy, meat, aquatic products, grains and oils, fruits and vegetables and other food fields that require rapid testing, as well as in the cultivation and breeding fields.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Zhaoli XiaoChairman of the Board, General Manager, since 2022
• Mr. Kai WanChief Financial Officer
• Ms. Wentian LiDeputy General Manager, Secretary of the Board, Director, since 2023
• Ms. Zhiying ChenDeputy General Manager, Director, since 2022
• Mr. Jinlong ZhangDeputy General Manager
• Ms. Xili WangDirector
• Ms. Ying XiongIndependent Director
• Mr. Ruobin YuanIndependent Director
• Mr. Wanjun ZhouIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.